Read More

Celyad Oncology Q4 2022 Business Update And 2023 Outlook; As Of Dec 31, 2022, The Co. Ended The Year With An Unaudited Treasury Position Of $13.3M; Co. Is Now Prioritizing Discovery Endeavors To Tackle The Major Current Limitations Of CAR T-Cell Therap…

Celyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and intellectual property The

CYAD

Read More

Cellectis Announces Pricing Of Follow-On $20.2M Public Offering Of 8.8M American Depositary Shares At A Price Of $2.50/ADS; Plans To Use ~$17M Of Proceeds To Fund The Continued Clinical Development Of UCART 123, UCART22, UCART20x22, And UCARTCS1

Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces

CLLS

Read More

Reported Late Thursday, Marathon Digital Holdings Announces 687 Bitcoin Produced In January, Up 45% MoM; Increased Unrestricted Cash To $133.8M And Increased Unrestricted Bitcoin Holdings To 8,090 BTC As Of January 31; Mining Operation Updates

Produced a Record 687 BTC in January 2023, 45% Increase from the Prior Month Increased Unrestricted Cash to $133.8 Million and Increased Unrestricted Bitcoin Holdings to 8,090 BTC as of January

MARA

Read More

Reported Late Thursday, Avalo Therapeutics Announces Pricing Of $15M Public Offering Of 3.77M Shares Of Common Stock And Warrants To Purchase 3.77M Shares Of Stock At A Price Of $3.98/ Share & Warrant, 1-Year Term Excursive Price Of $5/Share

Avalo Therapeutics, Inc. (NASDAQ:AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to an aggregate of 3,770,000 shares

AVTX

Read More

Reported Late Thursday, Edible Garden Announces Pricing Of Upsized $10.2M Public Offering Of 1,619,000 Units, Each Unit Consisting Of One Share Of Stock And One Warrant At A Price Of $6.30/Unit; Warrants In The Units Will Be Immediately Exercisable

Edible Garden AG Incorporated ("Edible Garden" or the "Company") (NASDAQ:EDBL, EDBLW)))), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce andEdible Garden AG Incorporated ("Edible Garden" or the "Company") (NASDAQ:EDBL, EDBLW)))), a

EDBL

Read More

‘Change To Classification Of Psilocybin And MDMA To Enable Prescribing By Authorized Psychiatrists’; Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change – Australian Government Department Of Health And Aged Care

https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA

CMPS